Diagnosis and Management of Peritoneal Metastases from Ovarian Cancer

Table 2

Survival rates in HYPERO study. Adapted from [87].

Time-point HIPEC used	n	OS (m)	2 years %	5 years %
Overall	141	30.3	49.1	25.4
Frontline	26	41.7	57.0	33.3
Interval debulking	19	68.6	80.4	50.2
Consolidation	12	53.7	63.6	42.4
Recurrence	83	23.5	40.9	18.0

OS: overall survival.